

Listing of Claims:

The following Listing of Claims replaces all prior versions, and listings, of claims in the application:

Claim 1 (original): A peptide, in substantially isolated form, which substantially includes the amino-terminal amino acid sequence: LQTPQPLLQVMMEPQGD-OH (SEQ ID 1); MPQNFYKLPQM (SEQ ID 2); VLEMKFPPPPQETVT (SEQ ID 3); LKPFPKLKVEVFFFP (SEQ ID 4); SEQP (SEQ ID 5); DKE (SEQ ID 6); DPPPPQS (SEQ ID 7); LNF (SEQ ID 8); VLPPNVG (SEQ ID 9); KYKLQPE (SEQ ID 10); SEEMP (SEQ ID 11); DSQPPV (SEQ ID 12); FPPPK (SEQ ID 13); VMEV (SEQ ID 14); DLEMPVLPVEPFFV (SEQ ID 15); LFFFLPVNVLP (SEQ ID 16); MQPPPLP (SEQ ID 17); DQPPDVEKPDLPFQVQS (SEQ ID 18); VYPFTGPIPN (SEQ ID 19); SLPQNILPL (SEQ ID 20); TQTPVVPPF (SEQ ID 21); LQPEIMGVPKVKETMVPK (SEQ ID 22); HKEMPFKYPVEPFTESQ (SEQ ID 23); SLTLTDVEKLHLPLPLVQ (SEQ ID 24); SWMHQPP (SEQ ID 25); QLPPTVMFP (SEQ ID 26); MHQPPQPLPPTVMFP (SEQ ID 27); PQSVLS (SEQ ID 28); LSQPKVLPVPQKAVPQRDMPIQ (SEQ ID 29); AFLLYQE (SEQ ID 30); FLLYQEPVLGPVR (SEQ ID 31); RGPFPILV (SEQ ID 32); ATFNRYQDDHGEEILKSL (SEQ ID 33).

Claim 2 (original): A peptide, in substantially isolated form, which substantially includes the amino acid sequence: LQTPQPLLQVMMEPQGD (SEQ ID 1); MPQNFYKLPQM (SEQ ID 2); VLEMKFPPPPQETVT (SEQ ID 3); LKPFPKLKVEVFFFP (SEQ ID 4); DPPPPQS (SEQ ID 7); VLPPNVG (SEQ ID 9); KYKLQPE (SEQ ID 10);

DSQPPV (SEQ ID 12); DLEMPVLPVEPFFV (SEQ ID 15), LFFFLPVVNVLP (SEQ ID 16); MQPPPLP (SEQ ID 17); DQPPDVEKPDLPFQVQS (SEQ ID 18).

Claim 3 (original): A peptide, in substantially isolated form, which substantially entirely consists of the amino acid sequence: LQTPQPLLQVMMEPQGD (SEQ ID 1); MPQNFYKLPQM (SEQ ID 2); VLEMKFPPPQETVT (SEQ ID 3); LKPFKLVKVEVFFFP (SEQ ID 4); SEQP (SEQ ID 5); DKE (SEQ ID 6); DPPPPQS (SEQ ID 7); LNF (SEQ ID 8); VLPPNVG (SEQ ID 9); KYKLQPE (SEQ ID 10); SEEMP (SEQ ID 11); DSQPPV (SEQ ID 12); FPPPK (SEQ ID 13); VMEV (SEQ ID 14); DLEMPVLPVEPFFV (SEQ ID 15); LFFFLPVVNVLP (SEQ ID 16); MQPPPLP (SEQ ID 17) ; DQPPDVEKPDLPFQVQS (SEQ ID 18); VYPFTGPIP (SEQ ID 19); SLPQNILPL (SEQ ID 20); TQTPVVPPF (SEQ ID 21); LQPEIMGVVKVETMVPK (SEQ ID 22); HKEMPFKYPVEPFTESQ (SEQ ID 23); SLTLTDVEKLHLPLPLVQ (SEQ ID 24); SWMHQPP (SEQ ID 25); QLPPTVMFP (SEQ ID 26); MHQPPQPLPPTVMFP (SEQ ID 27); PQSVLS (SEQ ID 28); LSQPKVLPVPQKAVPQRDMPIQ (SEQ ID 29); AFLLYQE (SEQ ID 30); FLLYQEPVLGPVR (SEQ ID 31); RGPFPILV (SEQ ID 32); ATFNRYQDDHGEEILKSL (SEQ ID 33).

Claim 4 (previously presented): A peptide according to claim 1 when obtained by a synthetic process.

Claim 5 (original): A peptide obtained by a synthetic process, which substantially includes the amino-terminal amino acid sequence: LQTPQPLLQVMMEPQGD-OH (SEQ

ID 1); MPQNFYKLPQM (SEQ ID 2); VLEMKFPPPPQETVT (SEQ ID 3);
LKPFPKLKVEVFFFP (SEQ ID 4); SEQP (SEQ ID 5); DKE (SEQ ID 6); DPPPPQS
(SEQ ID 7); LNF (SEQ ID 8); VLPPNVG (SEQ ID 9); KYKLQPE (SEQ ID 10); SEEMP
(SEQ ID 11); DSQPPV (SEQ ID 12); FPPPK (SEQ ID 13); VVMEV (SEQ ID 14);
DLEMPVLPVEPFFV (SEQ ID 15); LFFFLPVNVLP (SEQ ID 16); MQPPPLP (SEQ ID
17) ; DQPPDVEKPDLPFQVQS (SEQ ID 18); VYPFTGPIPN (SEQ ID 19);
SLPQNILPL (SEQ ID 20); TQTPVVVPPF (SEQ ID 21); LQPEIMGVPKVKETMVPK
(SEQ ID 22); HKEMPFKYPVEPFTESQ (SEQ ID 23); SLTLTDVEKHLPLPLVQ (SEQ
ID 24); SWMHQPP (SEQ ID 25); QPLPPTVMFP (SEQ ID 26); MHQPPQPLPPTVMFP
(SEQ ID 27); PQSVLS (SEQ ID 28); LSQPKVLPVPQKAVPQRDMPIQ (SEQ ID 29);
AFLLYQE (SEQ ID 30); FLLYQEPVLGPVR (SEQ ID 31); RGPFFILV (SEQ ID 32);
ATFNRYQDDHGEEILKSL (SEQ ID 33).

Claim 6 (original): A peptide obtained by a synthetic process, which substantially
includes the amino acid sequence: LQTPQPLLQVMMEPQGD-OH (SEQ ID 1);
MPQNFYKLPQM (SEQ ID 2); VLEMKFPPPPQETVT (SEQ ID 3); LKPFPKLKVEVFFFP
(SEQ ID 4); DPPPPQS (SEQ ID 7); VLPPNVG (SEQ ID 9); KYKLQPE (SEQ ID 10);
DSQPPV (SEQ ID 12); DLEMPVLPVEPFFV (SEQ ID 15); LFFFLPVNVLP (SEQ ID
16); MQPPPLP (SEQ ID 17) ; DQPPDVEKPDLPFQVQS (SEQ ID 18).

Claim 7 (original): A peptide obtained by a synthetic process, which substantially
entirely consists of the amino acid sequence: LQTPQPLLQVMMEPQGD-OH (SEQ ID
1); MPQNFYKLPQM (SEQ ID 2); VLEMKFPPPPQETVT (SEQ ID 3);

LKPFKPKLKEVFPFP (SEQ ID 4); SEQP (SEQ ID 5); DKE (SEQ ID 6); DPPPPQS (SEQ ID 7); LNF (SEQ ID 8); VLPPNVG (SEQ ID 9); KYKLQPE (SEQ ID 10); SEEMP (SEQ ID 11); DSQPPV (SEQ ID 12); FPPPK (SEQ ID 13); VVMEV (SEQ ID 14); DLEMPVLPVEPFPFV (SEQ ID 15); LFFFLPVVNVLP (SEQ ID 16); MQPPPLP (SEQ ID 17); DQPPDVEKPDLPFQVQS (SEQ ID 18); VYPFTGPIPN (SEQ ID 19); SLPQNILPL (SEQ ID 20); TQTPVVVPPF (SEQ ID 21); LQPEIMGVPKVKETMVPK (SEQ ID 22); HKEMPFKYPVEPFTESQ (SEQ ID 23); SLTLTDVEKLHLPLPLVQ (SEQ ID 24); SWMHQPP (SEQ ID 25); QPLPPTVMFP (SEQ ID 26); MHQPPQPLPPTVMFP (SEQ ID 27); PQSVLS (SEQ ID 28); LSQPKVLPVPQKAVPQRDMPIQ (SEQ ID 29); AFLLYQE (SEQ ID 30); FLLYQEPVLGPVR (SEQ ID 31); RGPFPILV (SEQ ID 32); ATFNRYQDDHGEEILKSL (SEQ ID 33).

Claim 8 (original): A peptide comprising: NH₂-(Ac)CLQTPQPLLQVMMEPQGD-OH (SEQ ID 34); NH₂-(Ac)CMPQNFYKLPQM-OH (SEQ ID 35); NH₂-(Ac)CVLEMKFPPPPQETVT-OH (SEQ ID 36); NH₂-(Ac)CLKPFKPKLKEVFPFP-OH (SEQ ID 37); NH₂-SEQPGGGC-OH (SEQ ID 38); NH₂-(Ac)CGVLPPNVG-OH (SEQ ID 39); NH₂-(Ac)CGGGKYKLQE-OH (SEQ ID 40); NH₂-(Ac)CGGGSEEMP(amide)-OH (SEQ ID 41); NH₂-(Ac)CGGGDSQPPV-OH (SEQ ID 42); NH₂-CFPPPKGGGC-OH (SEQ ID 43); NH₂-(Ac)CGGGVVMEV-OH (SEQ ID 44); NH₂-(Ac)CDLEMPVLPVEPFPFV-OH (SEQ ID 45); NH₂-(Ac)CLFFFLPVVNVLP-OH (SEQ ID 46); NH₂-(Ac)CMQPPPLP-OH (SEQ ID 47); NH₂-(Ac)CDQPPDVEKPDLPFQVQS-OH (SEQ ID 48); NH₂-(Ac)CGAFLLYQE-OH (SEQ ID 49); NH₂-(Ac)CATFNRYQDDHGEEILKSL-OH (SEQ ID 50).

Claims 9-20 (canceled)

Claim 21 (previously presented): A method of treating disorders of the central nervous system and/or of the immune system, comprising administering a therapeutically effective amount of a peptide according to claim 1 to a patient.

Claim 22 (previously presented): A composition comprising a peptide according to claim 1 in combination with a physiologically acceptable carrier.

Claim 23 (previously presented): A composition comprising two or more peptides according to claim 1 in combination with a physiologically acceptable carrier.

Claim 24 (previously presented): A composition according to claim 22 in a form suitable for injection.

Claim 25 (previously presented): A composition according to claim 22 in a form suitable for absorption through the mucosa of the oral/nasopharyngeal cavity and/or in a form suitable for absorption in the alimentary canal.

Claim 26 (previously presented): A composition according to claim 22 in the form of a tablet, lozenge, gel, patch or plaster.

Claim 27 (previously presented): A composition according to claim 22 in a form suitable for topical application.

Claims 28-35 (canceled)